Reynaert Research SRL
Reynaert Research reported total assets of 46,825 € at the end of the 2026 financial year (annual accounts filed with the NBB on 28 Oct 2026).
The score of Reynaert Research shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Total assets +36 %
Accounts of the company itself (not consolidated).
The full file covers 12 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Reynaert Research's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 28 Oct 2026
- Year ended 31 Mar 2025filed on 23 Oct 2025
- Year ended 31 Mar 2024filed on 15 Oct 2024
- Year ended 31 Mar 2023filed on 26 Oct 2023
- Year ended 31 Mar 2022filed on 27 Oct 2022
Reynaert Research's financial analysis
- Solvency-71.1%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Reynaert Research
Reynaert Research's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0466.059.759
- VAT number
- BE0466059759
- Peppol
- Registered · 0208:0466059759 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 May 1999
- Registered office
- 9040 Ghent
- Latest accounts
- 2026 · filed on 28 Oct 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Reynaert Research (SRL) has been based in Ghent since 1999, active in: wholesale of pharmaceutical and medical goods. For 2026, it reports a net profit of 6,930 € and equity of −33,290 €; its revenue is not published. Its solvency stands at -71.1%, below the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Reynaert Research
Companies in the same business, of comparable size and area, outside its group.
- Noreva BE Wholesale of pharmaceutical and medical goods Ghent · balance sheet 99,431 €
- Zabrus Wholesale of pharmaceutical and medical goods Sint-Martens-Latem · balance sheet 119,641 €
- BVPM Distribution Andenne · balance sheet 20,739 €
- Ofuro Group Wholesale of pharmaceutical and medical goods Zaventem · balance sheet 48,053 €
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
- Trend Management et Marketing Wholesale of pharmaceutical and medical goods Waterloo · balance sheet 44,372 €
- Sanmedex Wholesale of pharmaceutical and medical goods Uccle · balance sheet 50,961 €
- Laboratoire Colman Wholesale of pharmaceutical and medical goods La Louvière · balance sheet 42,584 €
Frequently asked questions about Reynaert Research
What is the revenue of Reynaert Research?
Reynaert Research files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Reynaert Research?
In Belgium, the VAT number is the company number prefixed with BE: BE0466059759 for Reynaert Research, if the company is VAT-registered. Its company number (CBE) is 0466.059.759.
Where is the registered office of Reynaert Research?
According to the CBE register, the registered office of Reynaert Research is in 9040 Ghent.
What is the equity of Reynaert Research?
At the close of the 2026 financial year, the equity of Reynaert Research amounts to -33,290 €, a solvency of -71.1% of total assets.
Who manages Reynaert Research?
The register lists 1 active mandates at Reynaert Research. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Reynaert Research
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →